Abstract
Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on highly active antiretroviral therapy (HAART). Design: Prospective, multicenter, study. Methods: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) + TDF + EFV and with a HIV-RNA <50 copies/mL were switched to the single-pill fixed-dose regimen (FDR) of FTC + TDF + EFV. Data were collected with SF-36 using visual analog scales. Results of the final (6 months) primary as-treated analysis are reported. Results: 212 patients (77.4% males) of mean age 45.8 years were enrolled; 202 completed the study. One month post switch to FDR the adherence rate increased significantly to 96.1% from a baseline value of 93.8% (P <0.01). The increase was steadily maintained throughout the study (96.2% at 6 months). QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P <0.0001). QoL significantly influenced adherence (P <0.0001). During FDR use the mean CD4 count increased from 556 to 605 cells/μL (P <0.0001). At the end of follow-up 98% of patients maintained HIV-RNA level <50 copies/mL and 100%
| Original language | English |
|---|---|
| Pages (from-to) | 115-125 |
| Number of pages | 11 |
| Journal | Patient Preference and Adherence |
| Volume | 4 |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- Adherence
- EFV/FTC/TDF
- Once-daily antiretroviral regimen
- Patient preferences
- QoL
- Single-pill regimen
ASJC Scopus subject areas
- Social Sciences (miscellaneous)
- Medicine (miscellaneous)
- Health Policy
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Cite this
One-pill once-a-day HAART : A simplification strategy that improves adherence and quality of life of HIV-infected subjects. / Airoldi, Monica; Zaccarelli, Mauro; Bisi, Luca; Bini, Teresa; Antinori, Andrea; Mussini, Cristina; Bai, Francesca; Orofino, Giancarlo; Sighinolfi, Laura; Gori, Andrea; Suter, Fredy; Maggiolo, Franco.
In: Patient Preference and Adherence, Vol. 4, 2010, p. 115-125.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - One-pill once-a-day HAART
T2 - A simplification strategy that improves adherence and quality of life of HIV-infected subjects
AU - Airoldi, Monica
AU - Zaccarelli, Mauro
AU - Bisi, Luca
AU - Bini, Teresa
AU - Antinori, Andrea
AU - Mussini, Cristina
AU - Bai, Francesca
AU - Orofino, Giancarlo
AU - Sighinolfi, Laura
AU - Gori, Andrea
AU - Suter, Fredy
AU - Maggiolo, Franco
PY - 2010
Y1 - 2010
N2 - Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on highly active antiretroviral therapy (HAART). Design: Prospective, multicenter, study. Methods: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) + TDF + EFV and with a HIV-RNA <50 copies/mL were switched to the single-pill fixed-dose regimen (FDR) of FTC + TDF + EFV. Data were collected with SF-36 using visual analog scales. Results of the final (6 months) primary as-treated analysis are reported. Results: 212 patients (77.4% males) of mean age 45.8 years were enrolled; 202 completed the study. One month post switch to FDR the adherence rate increased significantly to 96.1% from a baseline value of 93.8% (P <0.01). The increase was steadily maintained throughout the study (96.2% at 6 months). QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P <0.0001). QoL significantly influenced adherence (P <0.0001). During FDR use the mean CD4 count increased from 556 to 605 cells/μL (P <0.0001). At the end of follow-up 98% of patients maintained HIV-RNA level <50 copies/mL and 100%
AB - Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on highly active antiretroviral therapy (HAART). Design: Prospective, multicenter, study. Methods: Patients chronically treated with emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) + TDF + EFV and with a HIV-RNA <50 copies/mL were switched to the single-pill fixed-dose regimen (FDR) of FTC + TDF + EFV. Data were collected with SF-36 using visual analog scales. Results of the final (6 months) primary as-treated analysis are reported. Results: 212 patients (77.4% males) of mean age 45.8 years were enrolled; 202 completed the study. One month post switch to FDR the adherence rate increased significantly to 96.1% from a baseline value of 93.8% (P <0.01). The increase was steadily maintained throughout the study (96.2% at 6 months). QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was significantly associated with the perception of health status, presence of adverse events (AEs) and number of reported AEs (P <0.0001). QoL significantly influenced adherence (P <0.0001). During FDR use the mean CD4 count increased from 556 to 605 cells/μL (P <0.0001). At the end of follow-up 98% of patients maintained HIV-RNA level <50 copies/mL and 100%
KW - Adherence
KW - EFV/FTC/TDF
KW - Once-daily antiretroviral regimen
KW - Patient preferences
KW - QoL
KW - Single-pill regimen
UR - http://www.scopus.com/inward/record.url?scp=77954618054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954618054&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:77954618054
VL - 4
SP - 115
EP - 125
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
SN - 1177-889X
ER -